IMR Press / EJGO / Volume 38 / Issue 2 / DOI: 10.12892/ejgo3520.2017

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Overexpressed LEDGF is a novel biomarker of poor prognosis in patients with cervical cancer
Show Less
1 Department of Obstetrics and Gynecology, Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu, China
Eur. J. Gynaecol. Oncol. 2017, 38(2), 245–250; https://doi.org/10.12892/ejgo3520.2017
Published: 10 April 2017
Abstract

Lens epithelium-derived growth factor (LEDFG) can prevent cells apoptosis by activating stress proteins and anti-apoptotic protein, which are involved in the development of a variety of malignancies as some studies have shown. However, little is known about the role of LEDGF in cervical cancer. In this study, the authors collected 95 cases of the cervical cancer tissue samples and its matching tissue adjacent to carcinoma diagnosed by the Department of Pathology. mRNA expression of LEDFG in randomly selected 20 cervical cancer tissues and 20 adjacent normal tissues was detected by quantitative real-time PCR (qRT-PCR). LEDFG protein expression in randomly selected 20 cervical cancer tissues and 20 adjacent normal tissues was detected by immunohistochemistry (IHC) and Western Blot (WB). All patients were followed up for about three years. The authors found that both mRNA and protein expression level of LEDFG was significantly higher in cancer tissues compared with normal controls (p < 0.05) and this overexpression was significantly correlated with the histologic grade, the immersion depth of interstitial, the invasion of vessel, and lymph node status of cervical cancer. Furthermore, the three-year survival rate of 34 patients with LEDGF positive expression having a survival rate of three years was 57.6%. The survival rate of three years with negative expression was 91.7%. The survival rate of patients with LEDGF positive expression was significantly lower than those of the negative expression (p < 0.01). In conclusion, the present results suggest that LEDFG expression is an independent prognostic biomarker for cervical cancer.
Keywords
Cervical cancer
LEDGF
Immunohistochemistry
Western Blot
RT-PCT
Share
Back to top